Aarey Drugs & Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aarey Drugs & Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash paid for 95% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 67% of Healthcare companies in India.
Cash Locked Ratio
₹19For every ₹100 of sales, ₹19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹22 tied up three years earlier.
Less money tied up than 63% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
₹0Sales grew 14% in 3 years; of every extra ₹100 of sales, ₹0 became extra profit.
Lower than 84% of Healthcare companies in India.
Asset Productivity Ratio
+14% / +2%In 3 years sales changed by +14% while total assets changed by +2%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 83% of Healthcare companies in India.
Cash Cushion Ratio
−13%Debt, after subtracting cash, equals 13% of its market value (net debt).
Lower than 83% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 98% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Aarey Drugs & Pharmaceuticals Limited owes ₹0.49 for every ₹1 it owns. Net profit fell 1% in the year to Mar 2026, and grew 2% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
72.6Investors pay ₹72.6 for every ₹1 of Aarey Drugs & Pharmaceuticals Limited's yearly profit, higher than 84% of Healthcare companies in India.
P/B ratio
2.26The share price is 2.26 times Aarey Drugs & Pharmaceuticals Limited's book value per share, lower than 80% of Healthcare companies in India.
Market cap
₹340 CrThe total market value of all of Aarey Drugs & Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹150 CrWhat Aarey Drugs & Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹47.19Net worth divided by the number of shares. The share price of ₹106.73 is 2.3 times this, which is the P/B above.
Return on equity (ROE)
2.8%Aarey Drugs & Pharmaceuticals Limited earned 2.8% on its shareholders' money over the last year, lower than 87% of Healthcare companies in India.
Owes vs Owns
0.49×Aarey Drugs & Pharmaceuticals Limited owes ₹0.49 for every ₹1 it owns (low), higher than 82% of Healthcare companies in India.
Dividend yield
NoneAarey Drugs & Pharmaceuticals Limited does not currently pay a dividend.
Revenue growth
-0%Revenue fell 0% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Profit growth
-1%Net profit fell 1% in the year to Mar 2026, and grew 2% a year on average over 3 years.
Profit margin
0.8%Aarey Drugs & Pharmaceuticals Limited keeps ₹1 of every ₹100 of revenue as net profit.
Cash quality
2.6×Cash from Aarey Drugs & Pharmaceuticals Limited's business was 2.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
0.9×Aarey Drugs & Pharmaceuticals Limited's operating profit covered its interest costs 0.9 times in the year to Mar 2026.
Cash vs debt
Net debtAarey Drugs & Pharmaceuticals Limited had ₹47 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Aarey Drugs & Pharmaceuticals Limited's P/E ratio?
Investors pay ₹72.6 for every ₹1 of Aarey Drugs & Pharmaceuticals Limited's yearly profit, higher than 84% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aarey Drugs & Pharmaceuticals Limited: ₹340 Cr ÷ ₹150 Cr (31 Mar 2026) = 2.3.
What is Aarey Drugs & Pharmaceuticals Limited's return on equity?
Aarey Drugs & Pharmaceuticals Limited earned 2.8% on its shareholders' money over the last year, lower than 87% of Healthcare companies in India.
How much does Aarey Drugs & Pharmaceuticals Limited owe compared with what it owns?
Aarey Drugs & Pharmaceuticals Limited owes ₹0.49 for every ₹1 it owns (low), higher than 82% of Healthcare companies in India.
Does Aarey Drugs & Pharmaceuticals Limited pay a dividend?
No. Aarey Drugs & Pharmaceuticals Limited does not currently pay a dividend.
Is Aarey Drugs & Pharmaceuticals Limited's revenue growing?
Revenue fell 0% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.